Pacira Pharmaceuticals, Inc. Reports 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Pacira Pharma (PCRX) Misses Q4 EPS by 5c, Sales Beat
February 25, 2016 7:34 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.22, $0.05 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $69.3 million versus the consensus estimate of $68.4 million.
We finished 2015 with a solid performance in spite of the challenges we faced this past... More
